3230 related articles for article (PubMed ID: 6742864)
1. [The possible modes of action of TNF (tumor necrosis factor)].
Orita K
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1379-86. PubMed ID: 6742864
[TBL] [Abstract][Full Text] [Related]
2. [Definition of tumor-necrosis factor and its production mechanism].
Urushizaki I; Niitsu Y; Watanabe N
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1356-68. PubMed ID: 6378100
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor activity of tumor necrosis factor (TNF) in vitro and in vivo].
Haranaka K; Satomi N; Sakurai A
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1387-93. PubMed ID: 6742865
[TBL] [Abstract][Full Text] [Related]
4. Combination antitumor therapy with rabbit tumor necrosis factor and chemo- and immuno-therapeutic agents against murine tumors.
Gatanaga T; Takahashi K; Yamazaki M; Mizuno D; Abe S
Jpn J Cancer Res; 1985 Jul; 76(7):631-6. PubMed ID: 3928560
[TBL] [Abstract][Full Text] [Related]
5. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
6. Possible requirement of internalization in the mechanism of in vitro cytotoxicity in tumor necrosis serum.
Kull FC; Cuatrecasas P
Cancer Res; 1981 Dec; 41(12 Pt 1):4885-90. PubMed ID: 7306990
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells.
Corti A; Gasparri A; Sacchi A; Curnis F; Sangregorio R; Colombo B; Siccardi AG; Magni F
Cancer Res; 1998 Sep; 58(17):3866-72. PubMed ID: 9731496
[TBL] [Abstract][Full Text] [Related]
9. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha.
Bazzoni F; Regalia E
Cancer Res; 2001 Feb; 61(3):1050-7. PubMed ID: 11221832
[TBL] [Abstract][Full Text] [Related]
10. [Tumor necrosis factor: pleiotropic cytokine].
Chouaib S; Robinet E; Zyad A; Branellec D
Bull Cancer; 1992; 79(10):935-49. PubMed ID: 1292760
[TBL] [Abstract][Full Text] [Related]
11. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
12. Trophoblastic cell lines generated from tumour necrosis factor receptor-deficient mice reveal specific functions for the two tumour necrosis factor receptors.
Rasmussen CA; Pace JL; Banerjee S; Phillips TA; Hunt JS
Placenta; 1999; 20(2-3):213-22. PubMed ID: 10195744
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
[TBL] [Abstract][Full Text] [Related]
14. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma.
Atarashi Y; Yasumura S; Nambu S; Yoshio Y; Murakami J; Takahara T; Higuchi K; Watanabe A; Miyata K; Kato M
Hepatology; 1998 Jul; 28(1):57-67. PubMed ID: 9657097
[TBL] [Abstract][Full Text] [Related]
15. Endogenous production of TNF-like cytotoxic factor in BCG-primed mice by heterologous fibrinogen.
Kajikawa T; Shimada Y; Oshima H; Yamazaki M; Mizuno D
J Biol Response Mod; 1987 Feb; 6(1):88-95. PubMed ID: 3559629
[TBL] [Abstract][Full Text] [Related]
16. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro.
Taverne J; Tavernier J; Fiers W; Playfair JH
Clin Exp Immunol; 1987 Jan; 67(1):1-4. PubMed ID: 3621669
[TBL] [Abstract][Full Text] [Related]
18. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death.
Wu Y; Tewari M; Cui S; Rubin R
J Cell Physiol; 1996 Sep; 168(3):499-509. PubMed ID: 8816904
[TBL] [Abstract][Full Text] [Related]
19. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
Inagawa H; Nishizawa T; Honda T; Nakamoto T; Takagi K; Soma G
Anticancer Res; 1998; 18(5D):3957-64. PubMed ID: 9854510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
